Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 20354780)

1.

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI, Barrett-Lee P.

Breast Cancer Res Treat. 2011 Feb;125(3):659-69. doi: 10.1007/s10549-010-0857-4. Epub 2010 Mar 31.

PMID:
20354780
2.

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.

Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI.

Clin Exp Metastasis. 2007;24(3):157-67. Epub 2007 Mar 30.

PMID:
17394086
3.

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI.

Breast Cancer Res Treat. 2006 Jun;97(3):263-74. Epub 2005 Dec 7.

PMID:
16333527
4.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.

BMC Cancer. 2012 Oct 6;12:458. doi: 10.1186/1471-2407-12-458.

5.

Cellular characterization of a novel focal adhesion kinase inhibitor.

Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT.

J Biol Chem. 2007 May 18;282(20):14845-52. Epub 2007 Mar 28.

6.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

8.

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI.

Int J Cancer. 2006 Jan 15;118(2):290-301.

PMID:
16080193
9.

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI.

Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21.

PMID:
18493848
10.

TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.

Golubovskaya VM, Virnig C, Cance WG.

Mol Carcinog. 2008 Mar;47(3):222-34.

PMID:
17849451
11.

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN.

Mol Carcinog. 2007 Jun;46(6):488-96.

PMID:
17219439
12.

Evidence for activation of BK Ca channels by a known inhibitor of focal adhesion kinase, PF573228.

So EC, Wu KC, Liang CH, Chen JY, Wu SN.

Life Sci. 2011 Nov 7;89(19-20):691-701. doi: 10.1016/j.lfs.2011.08.013. Epub 2011 Sep 8.

PMID:
21925512
13.

Focal adhesion kinase inhibitors are potent anti-angiogenic agents.

Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC, Addison CL.

Mol Oncol. 2011 Dec;5(6):517-26. doi: 10.1016/j.molonc.2011.10.004. Epub 2011 Oct 20.

14.

Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.

Cowell LN, Graham JD, Bouton AH, Clarke CL, O'Neill GM.

Oncogene. 2006 Dec 7;25(58):7597-607. Epub 2006 Jun 26.

PMID:
16799644
15.

Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.

Wang F, Nohara K, Olivera A, Thompson EW, Spiegel S.

Exp Cell Res. 1999 Feb 25;247(1):17-28.

PMID:
10047444
16.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83.

17.

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F.

Cancer Res. 2008 Mar 15;68(6):1935-44. doi: 10.1158/0008-5472.CAN-07-5155.

18.
19.

Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events.

Mukhopadhyay NK, Gordon GJ, Chen CJ, Bueno R, Sugarbaker DJ, Jaklitsch MT.

J Cell Mol Med. 2005 Apr-Jun;9(2):387-97.

PMID:
15963258
20.

Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells.

Bartholomew PJ, Vinci JM, DePasquale JA.

J Steroid Biochem Mol Biol. 1998 Nov;67(3):241-9.

PMID:
9879983
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk